Official Japanese guidelines for the use of infliximab for rheumatoid arthritis

Modern Rheumatology

Volumn 15, Issue 1, 2005, Pages 4-8

  Miyasaka, Nobuyuki ^a   Takeuchi, Tsutomu ^b   Eguchi, Katsumi ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Guideline; Infliximab; Rheumatoid arthritis (RA); Tuberculosis (TB); Tumor necrosis factor (TNF )

Indexed keywords

ADRENALIN; BCG VACCINE; CHIMERIC ANTIBODY; CORTICOSTEROID; COTRIMOXAZOLE; DIPHENHYDRAMINE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; OXYGEN; PARACETAMOL; PREDNISOLONE; TUBERCULIN; TUMOR NECROSIS FACTOR ANTIBODY;

ALGORITHM; CHILD HEALTH CARE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG USE; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; EXTRAPULMONARY TUBERCULOSIS; HEALTH STATUS; HUMAN; INCIDENCE; INFECTION RISK; JAPAN; LIVER TOXICITY; LUNG TUBERCULOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SKIN TEST; SOCIOECONOMICS; SYSTEMIC DISEASE; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

EID: 14544304999     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-004-0357-7     Document Type: Short Survey

References (20)

1. Maini RN, Breedveld F, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
2. Maini RN, St Clair EW, Breedveld FC, Furst DE, Kalden JR, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedfveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000;343:1594-62.
4. Keane JK, Gershon S, Rharm D, Wise RP, Mirabile-Levens E, Kasznica J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-379.
6. World Health Organization. WHO report. Global tuberculosis control - surveillance, planning, financing. http//www.who.int/tb/publications/ global-report/2004/en
7. Ministry of Health, Labor, and Welfare, Japan. Report (in Japanese). http://www.jata.or.jp/rit/rj/03toukei.jtml
8. Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis (in Japanese). Ensho 1996;16:437-8.
9. Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1995;36:2004-9.
10. Liam CK, Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992;1:379-85.
11. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 1994;21:246-51.
12. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996;23:1186-8.
13. Ogawa J, Hariga MI, Nagasaka N, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis carinii pneumonia in patients with connective tissue diseases undergoing high-dose corticosteroid therapy. Mod Rheumatol; in press.
14. Bergin CJ, Wirth RL, Berry GJ, Castellino RA. Pneumocystis carinii pneumonia: CT and HRCT observations. J Comput Assist Tomogr, 1990;14:756-9.
15. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1-3) β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996;3:197-9.
16. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003;98:1315-24.
17. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-27.
18. Carmona L, Hernandez-Garcia C, Vadillp C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
19. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lance Infect Dis 2003;3:148-55.
20. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: Implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62(suppl II):iI37-42.